Simplexvirus

• 

  Subject Areas on Research

  • A herpes simplex virus 1 integration site in the mouse genome defined by somatic cell genetic analysis. 
  • A real-time PCR assay to identify and discriminate among wild-type and vaccine strains of varicella-zoster virus and herpes simplex virus in clinical specimens, and comparison with the clinical diagnoses. 
  • ACIDFORM inactivates herpes simplex virus and prevents genital herpes in a mouse model: optimal candidate for microbicide combinations. 
  • Abortive and productive infections of human mononuclear phagocytes by type I herpes simplex virus. 
  • Acyclovir-resistant herpes simplex virus keratouveitis after penetrating keratoplasty. 
  • Age distribution of latent herpes simplex virus 1 and varicella-zoster virus genome in human nervous tissue. 
  • Airway injury in lung disease pathophysiology: selective depletion of airway stem and progenitor cell pools potentiates lung inflammation and alveolar dysfunction. 
  • Antigen-specific T-lymphocyte function after cord blood transplantation. 
  • Attenuation of herpes simplex virus neurovirulence with picornavirus cis-acting genetic elements. 
  • C3b receptor activity on transfected cells expressing glycoprotein C of herpes simplex virus types 1 and 2. 
  • Complement component C3b binds directly to purified glycoprotein C of herpes simplex virus types 1 and 2. 
  • Conjunctival pseudotumor caused by herpes simplex virus infection. 
  • Constitutively active retinoid receptors exhibit interfamily and intrafamily promoter specificity. 
  • Cytokine expression in vivo during murine herpetic stromal keratitis. Effect of protective antibody therapy. 
  • Depression of human monocyte chemotaxis by herpes simplex and influenza viruses. 
  • Development of topical microbicides for prevention of human immunodeficiency virus and herpes simplex virus. 
  • Diagnosis and Treatment of Acute Retinal Necrosis: A Report by the American Academy of Ophthalmology. 
  • Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. 
  • Effect of herpes simplex virus types 1 and 2 on surface expression of class I major histocompatibility complex antigens on infected cells. 
  • Fulminant herpes simplex viral hepatitis: ultrasound and CT imaging appearance and a review of the imaging literature. 
  • Glycoprotein C of herpes simplex virus 1 is an inhibitor of the complement cascade. 
  • HSV-1 retinitis and delayed hypersensitivity in DBA/2 and C57BL/6 mice. 
  • Herpes simplex keratitis in patients with acquired immune deficiency syndrome. 
  • Herpes simplex retinitis in the mouse. Clinicopathologic correlations. 
  • Herpes simplex virus (HSV)-mediated ICAM-1 gene transfer abrogates tumorigenicity and induces anti-tumor immunity. 
  • Herpes simplex virus hepatitis after renal transplantation. 
  • Human Trial of a Genetically Modified Herpes Simplex Virus for Rapid Detection of Positive Peritoneal Cytology in the Staging of Pancreatic Cancer. 
  • Hypertrophic herpes simplex virus in HIV patients. 
  • Identification of focal viral infections by confocal microscopy for subsequent ultrastructural analysis. 
  • Incidence of Herpesvirus hominis antibodies among blood donor populations. 
  • Induction of cell stress through gene transfer of an engineered heat shock transcription factor enhances tumor immunogenicity. 
  • Inflammation and herpes simplex virus: release of a chemotaxis-generating factor from infected cells. 
  • Inflammation and viral infection: chemotactic activity resulting from the interaction of antiviral antibody and complement with cells infected with herpes simplex virus. 
  • Interaction between cyclic nucleotides and herpes simplex viruses: productive infection. 
  • Killing of normal melanocytes, combined with heat shock protein 70 and CD40L expression, cures large established melanomas. 
  • Mandelic acid condensation polymer: novel candidate microbicide for prevention of human immunodeficiency virus and herpes simplex virus entry. 
  • Molecular basis of latency in pathogenic human viruses. 
  • Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1. 
  • Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. 
  • Neutralization of sensitized virus by purified components of complement. 
  • Neutralization of sensitized virus by the fourth component of complement. 
  • Persistent infection with neurotropic herpes viruses and cognitive impairment. 
  • Prevention of herpes keratitis by monoclonal antibodies specific for discontinuous and continuous epitopes on glycoprotein D. 
  • Priming for virus-specific CD8+ but not CD4+ cytotoxic T lymphocytes with synthetic lipopeptide is influenced by acylation units and liposome encapsulation. 
  • Production of chemotactic factor and lymphotoxin by human leukocytes stimulated with Herpes simplex virus. 
  • Rasmussen's syndrome: a study of potential viral etiology. 
  • Recognition by and in vitro induction of cytotoxic T lymphocytes against predicted epitopes of the immediate-early protein ICP27 of herpes simplex virus. 
  • Replication of type I herpes simplex virus in primary cultures of hairy cell leukemic leukocytes. 
  • Safety of High-dose Acyclovir in Infants With Suspected and Confirmed Neonatal Herpes Simplex Virus Infections. 
  • Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus. 
  • Studies of viral antibody responses among Amish families. 
  • Synergy of adoptive T-cell therapy and intratumoral suicide gene therapy is mediated by host NK cells. 
  • The receptor protein tyrosine phosphatase mu, PTPmu, regulates histogenesis of the chick retina. 
  • Use of the polymerase chain reaction in the diagnosis of unsuspected herpes simplex viral pneumonia: report of a case. 
  • VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment. 
  • Validation of laboratory screening criteria for herpes simplex virus testing of cerebrospinal fluid.